Deutsche Bank AG Has $228.32 Million Stock Position in Kenvue Inc. (NYSE:KVUE)

Deutsche Bank AG grew its stake in Kenvue Inc. (NYSE:KVUE) by 4.4% during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 10,693,952 shares of the company’s stock after purchasing an additional 452,294 shares during the period. Deutsche Bank AG owned about 0.56% of Kenvue worth $228,316,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also recently added to or reduced their stakes in KVUE. Handelsbanken Fonder AB boosted its holdings in Kenvue by 2.9% during the fourth quarter. Handelsbanken Fonder AB now owns 742,184 shares of the company’s stock valued at $15,846,000 after purchasing an additional 21,222 shares in the last quarter. Alberta Investment Management Corp raised its stake in Kenvue by 23.2% during the fourth quarter. Alberta Investment Management Corp now owns 582,895 shares of the company’s stock worth $12,445,000 after acquiring an additional 109,700 shares in the last quarter. Longbow Finance SA lifted its holdings in shares of Kenvue by 5.0% during the fourth quarter. Longbow Finance SA now owns 280,568 shares of the company’s stock valued at $5,990,000 after acquiring an additional 13,287 shares during the period. Steward Partners Investment Advisory LLC boosted its stake in shares of Kenvue by 143.1% in the 4th quarter. Steward Partners Investment Advisory LLC now owns 47,938 shares of the company’s stock valued at $1,023,000 after purchasing an additional 28,216 shares in the last quarter. Finally, CORDA Investment Management LLC. grew its holdings in shares of Kenvue by 1.4% in the 4th quarter. CORDA Investment Management LLC. now owns 1,253,096 shares of the company’s stock worth $26,754,000 after purchasing an additional 17,466 shares during the last quarter. 97.64% of the stock is currently owned by institutional investors.

Kenvue Price Performance

Shares of KVUE stock opened at $24.47 on Friday. The firm’s 50 day moving average price is $23.13 and its two-hundred day moving average price is $22.56. The company has a debt-to-equity ratio of 0.66, a quick ratio of 0.69 and a current ratio of 1.00. Kenvue Inc. has a 52-week low of $17.67 and a 52-week high of $25.17. The stock has a market cap of $46.95 billion, a PE ratio of 46.17, a PEG ratio of 2.62 and a beta of 1.02.

Kenvue (NYSE:KVUE) last announced its quarterly earnings results on Thursday, May 8th. The company reported $0.24 earnings per share for the quarter, beating analysts’ consensus estimates of $0.23 by $0.01. The business had revenue of $3.74 billion for the quarter, compared to the consensus estimate of $3.69 billion. Kenvue had a net margin of 6.66% and a return on equity of 20.97%. Kenvue’s revenue for the quarter was down 3.9% on a year-over-year basis. During the same period last year, the company posted $0.28 EPS. As a group, analysts forecast that Kenvue Inc. will post 1.14 EPS for the current year.

Kenvue Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Wednesday, May 28th. Investors of record on Wednesday, May 14th will be given a $0.205 dividend. This represents a $0.82 dividend on an annualized basis and a dividend yield of 3.35%. The ex-dividend date of this dividend is Wednesday, May 14th. Kenvue’s dividend payout ratio is currently 154.72%.

Analyst Ratings Changes

A number of equities analysts have commented on KVUE shares. Canaccord Genuity Group boosted their price target on shares of Kenvue from $24.00 to $29.00 and gave the company a “buy” rating in a research report on Wednesday, March 5th. UBS Group raised their price target on Kenvue from $24.00 to $25.00 and gave the company a “neutral” rating in a report on Friday. Redburn Atlantic started coverage on Kenvue in a research note on Thursday, April 10th. They issued a “neutral” rating and a $23.50 price objective on the stock. Barclays lowered their target price on Kenvue from $23.00 to $22.00 and set an “equal weight” rating for the company in a research note on Monday, April 14th. Finally, Royal Bank of Canada reiterated a “sector perform” rating and set a $24.00 price target on shares of Kenvue in a research report on Monday, February 3rd. Seven research analysts have rated the stock with a hold rating and five have given a buy rating to the company. According to MarketBeat.com, the stock currently has a consensus rating of “Hold” and a consensus price target of $25.25.

Kenvue Profile

Kenvue Inc operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands.